TABLE 3A:
Risk Factors Associated With Progression of Existing Inflammatory Bowel Disease After Liver Transplantation
| IBD Progression | ||||
|---|---|---|---|---|
| Risk Factors | Univariate Analysis HR (95% CI) | P | Multivariate Analysis HR (95% CI) | P |
| Demographics | ||||
| Age at LT per y | 0.997 (0.97–1.02) | 0.805 | - | - |
| Sex (M:F) | 1.17 (0.64–2.26) | 0.623 | - | - |
| Smoking (ever:never) | 1.73 (0.70–3.67) | 0.216 | - | - |
| Transplant-related variables | ||||
| CMV infection (Y:N) | 1.46 (0.76–2.69) | 0.247 | - | - |
| CMV mismatch (Y:N) | 2.20 (1.14–4.32) | 0.019 | 1.10 (0.66–1.82) | 0.701 |
| Renal dysfunction at the time of LT (serum Creatinine > 1.3) | 0.20 (0.01–0.95) | 0.041 | 0.74 (0.34–1.45) | 0.283 |
| Type of LT (living donor vs orthotopic liver transplantation) | 2.36 (0.95–5.09) | 0.063 | ||
| Immunosuppression | ||||
| Tacrolimus-based immunosuppression (vs cyclosporine-based) | 3.51 (1.84–7.20) | <0.001 | 4.06 (1.87–10.24) | <0.001 |
| Mycophenolate mofetil use at LT (Y:N) | 1.40 (0.78–2.51) | 0.261 | - | - |
| Azathioprine use at LT (Y:N) | 0.42 (0.23–0.76) | 0.005 | 0.52 (0.30–0.87) | 0.014 |
| IBD-related variables | ||||
| Peritransplant 5-ASA use (Y:N) | 1.27 (0.48–2.79) | 0.60 | - | - |